Prognostic value of histopathologic traits independent of stromal tumor-infiltrating lymphocyte levels in chemotherapy-naïve patients with triple-negative breast cancer
L W de Boo,K Jóźwiak,N D Ter Hoeve,P J van Diest,M Opdam,Y Wang,M K Schmidt,V de Jong,S Kleiterp,S Cornelissen,D Baars,R H T Koornstra,E D Kerver,T van Dalen,A D Bins,A Beeker,S M van den Heiligenberg,P C de Jong,S D Bakker,R C Rietbroek,I R Konings,R Blankenburgh,R M Bijlsma,A L T Imholz,N Stathonikos,W Vreuls,J Sanders,E H Rosenberg,E A Koop,Z Varga,C H M van Deurzen,A L Mooyaart,A Córdoba,E Groen,J Bart,S M Willems,V Zolota,J Wesseling,A Sapino,E Chmielik,A Ryska,A Broeks,A C Voogd,E van der Wall,S Siesling,R Salgado,G M H E Dackus,M Hauptmann,M Kok,S C Linn
DOI: https://doi.org/10.1016/j.esmoop.2024.102923
IF: 6.883
ESMO Open
Abstract:Background: In the absence of prognostic biomarkers, most patients with early-stage triple-negative breast cancer (eTNBC) are treated with combination chemotherapy. The identification of biomarkers to select patients for whom treatment de-escalation or escalation could be considered remains an unmet need. We evaluated the prognostic value of histopathologic traits in a unique cohort of young, (neo)adjuvant chemotherapy-naïve patients with early-stage (stage I or II), node-negative TNBC and long-term follow-up, in relation to stromal tumor-infiltrating lymphocytes (sTILs) for which the prognostic value was recently reported. Materials and methods: We studied all 485 patients with node-negative eTNBC from the population-based PARADIGM cohort which selected women aged <40 years diagnosed between 1989 and 2000. None of the patients had received (neo)adjuvant chemotherapy according to standard practice at the time. Associations between histopathologic traits and breast cancer-specific survival (BCSS) were analyzed with Cox proportional hazard models. Results: With a median follow-up of 20.0 years, an independent prognostic value for BCSS was observed for lymphovascular invasion (LVI) [adjusted (adj.) hazard ratio (HR) 2.35, 95% confidence interval (CI) 1.49-3.69], fibrotic focus (adj. HR 1.61, 95% CI 1.09-2.37) and sTILs (per 10% increment adj. HR 0.75, 95% CI 0.69-0.82). In the sTILs <30% subgroup, the presence of LVI resulted in a higher cumulative incidence of breast cancer death (at 20 years, 58%; 95% CI 41% to 72%) compared with when LVI was absent (at 20 years, 32%; 95% CI 26% to 39%). In the ≥75% sTILs subgroup, the presence of LVI might be associated with poor survival (HR 11.45, 95% CI 0.71-182.36, two deaths). We confirm the lack of prognostic value of androgen receptor expression and human epidermal growth factor receptor 2 -low status. Conclusions: sTILs, LVI and fibrotic focus provide independent prognostic information in young women with node-negative eTNBC. Our results are of importance for the selection of patients for de-escalation and escalation trials.